Athena M. Countouriotis

2017

In 2017, Athena M. Countouriotis earned a total compensation of $1.7M as Former Senior Vice President and Chief Medical Officer at Halozyme Therapeutics, a 10% decrease compared to previous year.

Compensation breakdown

Option Awards$550,000
Salary$236,493
Stock Awards$550,006
Other$323,773
Total$1,660,272

Countouriotis received $550K in stock awards, accounting for 33% of the total pay in 2017.

Countouriotis also received $550K in option awards, $236.5K in salary and $323.8K in other compensation.

Rankings

In 2017, Athena M. Countouriotis' compensation ranked 6,462nd out of 14,666 executives tracked by ExecPay. In other words, Countouriotis earned more than 55.9% of executives.

ClassificationRankingPercentile
All
6,462
out of 14,666
56th
Division
Manufacturing
2,382
out of 5,768
59th
Major group
Chemicals And Allied Products
760
out of 2,074
63rd
Industry group
Drugs
586
out of 1,730
66th
Industry
Biological Products, Except Diagnostic Substances
106
out of 316
67th
Source: SEC filing on March 22, 2018.

Countouriotis' colleagues

We found four more compensation records of executives who worked with Athena M. Countouriotis at Halozyme Therapeutics in 2017.

2017

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

2017

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

2017

Harry Leonhardt

Halozyme Therapeutics

General Counsel

2017

Mark Gergen

Halozyme Therapeutics

Chief Operating Officer

You may also like